Related Experiment Video
Updated: Jun 7, 2026
08:00
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Gene therapy for cystic fibrosis
Jane C Davies1, Eric W F W Alton
1Department of Gene Therapy, Imperial College London, Manresa Road, London SW3 6LR, UK. j.c.davies@imperial.ac.uk
Proceedings of the American Thoracic Society
|October 30, 2010
Summary
Cystic fibrosis (CF) gene therapy has shown partial success in correcting chloride secretion but not sodium hyperabsorption. Further research is needed to determine if these molecular improvements translate into clinical benefits for CF patients.
Area of Science:
- Pulmonary Medicine
- Genetics
- Biotechnology
Background:
- The first cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy trials began in 1993.
- Over 20 clinical trials using viral and nonviral gene transfer agents have been conducted.
- Previous trials focused on molecular or bioelectrical outcomes, primarily in the nasal or lower airways.
Purpose of the Study:
- To review the published literature on CFTR gene therapy.
- To discuss the limitations of gene therapy in the cystic fibrosis airway.
- To consider factors influencing the design of future clinical trials.
Main Methods:
- Review of published literature on CFTR gene therapy clinical trials.
- Analysis of outcome measures, including transgene mRNA expression and chloride secretion.
- Discussion of limitations and future trial design considerations.
Main Results:
- Partial correction of chloride secretion has been observed in some trials.
- Transgene mRNA expression has been detected.
- Sodium hyperabsorption has not been improved by current gene therapy approaches.
Conclusions:
- CFTR gene therapy has demonstrated proof-of-principle but has not yet translated into significant clinical benefit.
- Limitations in the CF airway present challenges for effective gene therapy delivery and efficacy.
- Further research and optimized clinical trial designs are necessary to advance CF gene therapy.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...